Why are ANN and HGH in focus today?

Highlights:

• Ansell acquired Kimberly-Clark’s personal protective equipment business for AU$974 million, aiming to expand its product range into scientific labs and safety eyewear.
• The deal is funded through a AU$400 million share placement and a potential additional AU$65 million from a share purchase plan, highlighting Ansell's strategic financial planning.
• Heartland Group Holdings successfully raises NZ$131 million in an institutional capital raising, demonstrating strong investor support and paving the way for future growth.

In a significant move, Ansell (ASX: ANN) has announced the acquisition of Kimberly-Clark Corporation’s personal protective equipment division, encompassing the renowned Kimtech and KleenGuard brands, for a deal valued at $US640 million ($974 million). This strategic purchase is set to expand Ansell's footprint in the personal protective equipment industry, venturing into new territories like scientific labs and safety eyewear.

Capital Boost for Expansion

To finance this acquisition, Ansell is set to raise AU$400 million through a fully underwritten share placement priced at AU$22.45 per share. This move is coupled with a plan to enhance the company's financial health further through a share purchase plan expected to garner up to AU$65 million. The pricing of the capital raising was determined at a 6% discount to the closing price just before the weekend, underscoring the company’s strategic financial planning to support this acquisition.

Strategic Growth and Synergies

Ansell, a leader in manufacturing single-use medical gloves and protective suits, views the acquisition as a significant expansion into sectors requiring high levels of protection, like scientific research and industrial safety. CEO Neil Salmon highlighted the decade-long interest in Kimberly-Clark’s division, emphasizing the swift action taken by Ansell to secure the deal amidst competitive bidding. With anticipated annual synergies of $US10 million by the third year, Ansell is gearing up for integrated growth and enhanced market presence.

Broadening the Product Portfolio

The acquisition is poised to enrich Ansell’s product range, especially in scientific and industrial applications, marking a strategic extension beyond its traditional offerings. This move is seen as a vital step in diversifying Ansell’s portfolio, leveraging its reputation established during the pandemic when demand for its protective medical gear soared.

Market and Financial Implications

Following the announcement, Ansell shares were temporarily halted, reflecting the market’s anticipation of the deal's impact. The acquisition, expected to close in the September quarter, promises to strengthen Ansell’s market position, offering new growth avenues in the burgeoning sectors of scientific research and industrial safety.

Heartland Group's Financial Strategy

Simultaneously, Heartland Group Holdings Ltd (ASX: HGH) has caught the market's attention with a 5% dip in share price to AU$1.06, after successfully completing an institutional capital raise. The NZ-based financial services entity raised approximately NZ$131 million, signaling robust support from institutional investors. With a 98% uptake in entitlements by eligible institutional shareholders, Heartland is now poised to execute its retail entitlement offer, underlining its strategic financial maneuvers for growth and expansion.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com